The most frequent cause of infectious disease-related mortality globally is tuberculosis (TB), a multisystemic disease with a wide range of presentations and symptoms. Around 12% of extrapulmonary TB cases and 1–3% of all TB cases are caused by abdominal TB. The issue of antituberculosis drug-induced liver injury (ATLI), which has long been a challenge in the management of TB infection, is one of increased significance. The major steps to reduce the occurrence of ATLI are to identify the possible risk factors of hepatotoxicity and to provide an appropriate weight-based anti-tuberculosis treatment (ATT). Dosage adjustment in the intensive phase helps overcome the complications of liver injury associated with these drugs. Withdrawal of the drugs followed by reintroduction in a weight based manner, once the LFT is normal, helps achieve tolerance to the drugs.

Bincy Charley is a Doctor of Pharmacy (Pharm.D) graduate from Kerala University of Health Sciences. She completed her internship at Believers Church Medical College Hospital, Tiruvalla, Kerala, where she gained hands-on clinical experience across various specialties. She brings nearly two years of professional experience as a Clinical Pharmacist at Tiruvalla Medical Mission Hospital, Kerala, where she was actively involved in patient care, medication therapy management, and interdisciplinary healthcare collaboration. Bincy has now been admitted to the Master’s in Clinical Research program at Rush University Medical Center, Chicago, Illinois, USA, marking the next step in her academic and professional journey toward advancing her expertise in clinical research and evidence-based medicine.